Department of Interventional Ultrasound, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Ultrasound Diagnostic Department, 92493 Military Hospital of the Chinese People's Liberation Army, Beijing; China.
Int J Hyperthermia. 2024;41(1):2308079. doi: 10.1080/02656736.2024.2308079. Epub 2024 Feb 12.
The effect of microwave ablation (MWA) for the renal cell carcinoma (RCC) in Von Hippel-Lindau (VHL) disease is unclear.
To assess the safety, Technique efficacy, renal function and oncological outcome of MWA for RCC in VHL patients.
Consecutive patients with RCCs in VHL disease treated by MWA were retrospectively collected from November 2009 to October 2020. The technical efficacy rate and complications were assessed. The outcomes of pre- and post-ablative eGFR were compared. The local recurrent-free survival (LRFS), renal-cancer-free survival (RCFS), cancer-specific survival (CSS), overall survival (OS) and complications were presented.
A total of 10 patients (mean age, 39.0 years ± 10.7 [SD]; 3 women) with 28 RCCs (mean tumor size, 3.0 cm ± 0.34; mean tumor volume, 20.7 mL ± 43.3) treated with MWA were included. Th median follow-up time was 52 months(IQR:27-80). The overall technical efficacy rate was 100% with no major complications occurred. No significant statistical difference between pre-ablative and postablative creatinine level (102.0 µmol/ ± 30.4 vs 112.3 µmol/ ± 38.7, = 0.06), but the pre-ablative eGFR level was significantly higher than the post-ablative eGFR (78.0 mL/(min1.73m) ± 28.6 vs 72 mL/(min1.73m) ± 31.4, = 0.04), with the mean decrease of 5.86 ml/(min*1.73m). The local recurrent-free survival(LRFS) and renal-cancer-free survival (RCFS) were 100% and 60%, respectively. The cancer specifical survival (CSS) and overall survival (OS) were 95.5% and 100%, respectively.
Microwave ablation is a safe and feasible method for the treatment of RCC in VHL disease, preserving renal function and yielding satisfactory oncological outcomes.
微波消融（MWA）治疗 von Hippel-Lindau（VHL）病相关肾细胞癌（RCC）的效果尚不清楚。
评估 MWA 治疗 VHL 患者 RCC 的安全性、技术疗效、肾功能和肿瘤学结果。
回顾性收集 2009 年 11 月至 2020 年 10 月连续接受 MWA 治疗的 VHL 相关 RCC 患者资料。评估技术疗效率和并发症。比较消融前后估算肾小球滤过率（eGFR）的变化。报告局部无复发生存率（LRFS）、肾肿瘤无复发生存率（RCFS）、癌症特异性生存率（CSS）、总生存率（OS）和并发症。
共纳入 10 例（平均年龄 39.0 岁±10.7 岁；3 例女性）患者，共 28 个 RCC（平均肿瘤大小 3.0 cm±0.34 cm；平均肿瘤体积 20.7 ml±43.3 ml）接受 MWA 治疗。中位随访时间为 52 个月（IQR：27-80）。总的技术疗效率为 100%，无严重并发症发生。消融前后血肌酐水平无显著统计学差异（102.0 μmol/L±30.4 vs 112.3 μmol/L±38.7， = 0.06），但消融前 eGFR 水平明显高于消融后（78.0 ml/（min1.73m）±28.6 vs 72 ml/（min1.73m）±31.4， = 0.04），平均下降 5.86 ml/（min*1.73m）。局部无复发生存率（LRFS）和肾肿瘤无复发生存率（RCFS）分别为 100%和 60%。癌症特异性生存率（CSS）和总生存率（OS）分别为 95.5%和 100%。
微波消融是治疗 VHL 相关 RCC 的一种安全、可行的方法，能保留肾功能并获得满意的肿瘤学结果。
